AIDA Oncology develops machine-learning assays that analyze RNA expression from tumor biopsies to predict individual patient response to specific chemotherapy drugs. This technology provides clinicians with personalized Drug Sensitivity Scores to guide treatment selection, aiming to maximize therapeutic efficacy while minimizing patient toxicity. The platform enhances treatment confidence and improves patient outcomes by ensuring the most effective therapy is administered first.
Funding
$580K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer therapies often exhibit low efficacy, with only a fraction of treatments proving effective for individual patients. With over 300 cancer drugs available, selecting the most appropriate treatment for a patient is challenging, leading to suboptimal outcomes and increased healthcare costs.
Solution
Aida leverages machine-optimized algorithms to analyze the RNA expression profile of a patient's tumor, predicting the drugs most likely to be effective. By applying advanced bioinformatics and machine learning to tumor transcriptome data, Aida aims to improve the selection of cancer treatments, leading to better patient outcomes. The technology helps clinicians identify the right drug for the right patient, increasing the likelihood of a positive response. This approach reduces the trial-and-error associated with cancer treatment, minimizing ineffective treatments and associated costs.
Target Audience
The primary users are oncologists and healthcare providers seeking to improve cancer treatment efficacy and patient outcomes, as well as healthcare systems aiming to reduce costs associated with ineffective treatments.
Features
- Machine-optimized algorithms analyze RNA expression profiles from tumor samples.
- Predictive models identify likely drug responses based on individual patient tumor characteristics.
- Integrates tumor transcriptome and cell line data to enhance prediction accuracy.
- Aims to improve the effectiveness of prescribed cancer drugs.